Loading clinical trials...
Loading clinical trials...
A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections
Conditions
Interventions
IMI/REL FDC
Locations
33
United States
Arkansas Children's Hospital ( Site 1311)
Little Rock, Arkansas, United States
Children's Hospital of Orange County ( Site 1301)
Orange, California, United States
Rady Children's Hospital-San Diego ( Site 1305)
San Diego, California, United States
Our Lady of the Lake Hospital ( Site 1304)
Baton Rouge, Louisiana, United States
St. Louis Children's Hospital ( Site 1322)
St Louis, Missouri, United States
Duke University Medical Center ( Site 1317)
Durham, North Carolina, United States
Start Date
November 6, 2017
Primary Completion Date
July 28, 2020
Completion Date
August 11, 2020
Last Updated
February 6, 2024
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions